肺气肿治疗市场
肺气肿治疗市场：2026年市场规模约为54.1亿美元，2031年市场规模约为68.4亿美元；预测期复合年增长率为4.80%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
肺气肿治疗市场：2026年市场规模约为54.1亿美元，2031年市场规模约为68.4亿美元；预测期复合年增长率为4.80%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 4.8% | 机构预测 |
| 市场规模 | 2026 | USD 5.41 billion | 机构预测 |
| 市场规模 | 2031 | USD 6.84 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| emphysema_phenotype | centriacinar emphysema | 2025 | 58.340% |
| end_user | hospitals and clinics | 2025 | 61.230% |
| geography | North America | 2025 | 40.340% |
| route_of_administration | inhaled therapies | 2025 | 48.790% |
| treatment_type | medication | 2025 | 61.450% |
关键结论
- emphysema_phenotype 维度中，centriacinar emphysema 在 2025 年的公开份额为 58.34%。
- end_user 维度中，hospitals and clinics 在 2025 年的公开份额为 61.23%。
- geography 维度中，North America 在 2025 年的公开份额为 40.34%。
- route_of_administration 维度中，inhaled therapies 在 2025 年的公开份额为 48.79%。
- treatment_type 维度中，medication 在 2025 年的公开份额为 61.45%。
主要参与者
- AstraZeneca PLC
- GSK plc
- Novartis AG
- Boehringer Ingelheim GmbH
- Teva Pharmaceutical Industries Ltd.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising COPD and emphysema diagnoses | +1.100% | Global, with the highest incremental burden in China, India, and Sub-Saharan Africa | Short term (≤ 2 years) |
| Expansion of minimally invasive lung-volume reduction | +0.900% | North America, Western Europe, Japan, and early-stage Asia-Pacific | Medium term (2-4 years) |
| Growth of home-based oxygen and pulmonary rehabilitation | +0.700% | North America, the EU, and Australia | Medium term (2-4 years) |
| Novel anti-inflammatory and PDE3/4 therapies | +1.000% | United States, EU, and Japan, with wider Asia-Pacific reimbursement pending | Short term (≤ 2 years) |
| Earlier CT-based phenotyping and patient referral | +0.500% | North America and the EU | Medium term (2-4 years) |
| Remote monitoring and adherence-linked care pathways | +0.400% | North America, the EU, Australia, and urban Asia-Pacific | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High lifetime treatment cost and unequal reimbursement | -0.200% | Global, most acute in Asia-Pacific, the Middle East and Africa, and South America | Medium term (2-4 years) |
| Limited spirometry and underdiagnosis in emerging markets | -0.200% | Asia-Pacific, the Middle East and Africa, and South America | Short term (≤ 2 years) to Long term (≥ 4 years) |
| Narrow eligibility for bronchoscopic and surgical procedures | -0.100% | Global | Medium term (2-4 years) |
| Pneumothorax, procedural risk, and post-treatment capacity constraints | -0.100% | Global | Short term (≤ 2 years) to Medium term (2-4 years) |
报告关注的关键问题
What is the projected value of the emphysema treatment market by 2031?
The emphysema treatment market is projected to reach USD 6.84 billion by 2031, from USD 5.41 billion in 2026, at a CAGR of 4.80%. Medication, oxygen therapy, and procedures all contribute to this forecast.
Which emphysema treatment type is growing fastest?
Surgery is the fastest-growing treatment type, with a projected CAGR of 5.22% through 2031. Bronchoscopic and surgical lung-volume reduction support this expansion, particularly when medication offers limited benefit in advanced disease.
Why are biologics important in COPD-related emphysema care?
Mepolizumab reduced annualized moderate-to-severe exacerbations by 21% in the 804-patient MATINEE trial, supporting use in eosinophilic COPD. Biologics also create a treatment option for patients identified through phenotype assessment.
Which region is expected to grow fastest through 2031?
Asia-Pacific is forecast to grow at a CAGR of 6.45% through 2031. The emphysema treatment market is supported by China's large COPD population, expanding diagnostic activity, and wider reimbursement access in several countries.
What limits access to advanced emphysema treatment?
High biologic costs, uneven reimbursement, limited spirometry, and narrow procedure eligibility limit access in many countries. Annual biologic costs of USD 20,000 - 40,000 and limited specialist capacity can be particularly restrictive.
Which care setting is gaining importance for emphysema patients?
Specialty pulmonary centers are forecast to grow at a CAGR of 6.20% through 2031. Bronchoscopy suites, CT interpretation, and multidisciplinary oversight are concentrated in these specialized care settings.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence